The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Risperidone in the treatment of schizophrenia
Abstract
OBJECTIVE: The purpose of this study was to investigate the safety and efficacy of risperidone in the treatment of schizophrenic patients and determine its optimal dose. METHOD: This double-blind study included 388 schizophrenic patients drawn from 20 sites in the United States. Patients were randomly assigned to 8 weeks' treatment with placebo, one of four doses of risperidone (2, 6, 10, or 16 mg), or 20 mg of haloperidol daily. RESULTS: Clinical improvement (20% reduction in total scores on the Positive and Negative Syndrome Scale for Schizophrenia) at the study end point was shown by 35% of the patients receiving 2 mg of risperidone, 57% receiving 6 mg, 40% receiving 10 mg, and 51% receiving 16 mg; and by 30% receiving haloperidol and 22% receiving placebo. Statistically significant differences in clinical improvement were found between 6 and 16 mg of risperidone versus placebo and versus haloperidol. Positive symptom scores were significantly lower after 6, 10, and 16 mg of risperidone and 20 mg of haloperidol than placebo; negative symptom scores, however, were reduced significantly, compared with placebo, only after 6 and 16 mg of risperidone. The incidence of extra-pyramidal side effects (measured by the Extrapyramidal Symptom Rating Scale) was significantly higher in patients treated with 16 mg of risperidone or 20 mg of haloperidol than placebo. The results indicate that the optimal daily dose of risperidone for most schizophrenic patients in this study was 6 mg; this dose was as effective as 16 mg, and the incidence of extrapyramidal symptoms in patients receiving 6 mg of risperidone was no higher than that in patients receiving placebo. CONCLUSIONS: Risperidone is a safe antipsychotic that is effective against both the positive and negative symptoms of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Reliability and validity of the positive and negative syndrome scale for schizophrenics
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90038-8 · Cited by 1,007
Dopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602
Janssen, P. A., Niemegeers, C. J., Awouters, F., Schellekens, K. H., Megens, A. A., & Meert, T. F. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24408-1 · Cited by 468
Biochemical profile of risperidone, a new antipsychotic.
Leysen, J. E., Gommeren, W., Eens, A., de Chaffoy de Courcelles, D., Stoof, J. C., & Janssen, P. A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13416-2 · Cited by 411
The Role of Serotonin in Schizophrenia
Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.297 · Cited by 371
Claus, A., Bollen, J., Cuyper, H. D., Eneman, M., Malfroid, M., Peuskens, J., & Heylen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01473.x · Cited by 295
Risperidone: clinical safety and efficacy in schizophrenia.
Borison, R. L., Pathiraja, A., Diamond, B. I., & Meibach, R. C. (1992) · PubMed · Cited by 210
Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker
Reyntjens, A., Gelders, Y. G., Hoppenbrouwers, M. J. A., & Vanden Bussche, G. (1986) · Drug Development Research · doi:10.1002/ddr.430080124 · Cited by 192
A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten, T. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200062009 · Cited by 188
The positive-negative dimension in schizophrenia: its validity and significance.
Kay, & Opler, L. A. (1987) · PubMed · Cited by 121
Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients
Mesotten, F., Suy, E., Pietquin, M., et al. (1989) · Psychopharmacology · doi:10.1007/bf00589890 · Cited by 121
Bersani, G., Grispini, A., Marini, S., Pasini, A., Valducci, M., & Ciani, N. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199012000-00003 · Cited by 105
Castelão, J., Ferreira, L., Gelders, Y. G., et al. (1989) · Schizophrenia Research · doi:10.1016/0920-9964(89)90034-0 · Cited by 96
Müller-Spahn, F. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199201001-00048 · Cited by 58
Effect of ritanserin, a selective serotonin-S2 antagonist, on parkinsonian rest tremor
Hildebrand, J. G., & Delecluse, F. (1987) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 22
Cited by
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Clinical implications of Brief Psychiatric Rating Scale scores
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.4.366 · Cited by 896
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1994-06-01
- Volume
- 151
- Issue
- 6
- Pages
- 825-835
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W153750880
- Cited by
- 1,193
- References
- 21
- FWCI
- 61.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.